Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Return on Equity (2016 - 2017)

Historic Return on Equity for Eledon Pharmaceuticals (ELDN) over the last 4 years, with Q3 2017 value amounting to 0.35%.

  • Eledon Pharmaceuticals' Return on Equity rose 9600.0% to 0.35% in Q3 2017 from the same period last year, while for Sep 2017 it was 0.35%, marking a year-over-year increase of 9600.0%. This contributed to the annual value of 1.29% for FY2016, which is 7400.0% down from last year.
  • According to the latest figures from Q3 2017, Eledon Pharmaceuticals' Return on Equity is 0.35%, which was up 9600.0% from 0.72% recorded in Q2 2017.
  • Eledon Pharmaceuticals' 5-year Return on Equity high stood at 0.23% for Q4 2014, and its period low was 2.94% during Q1 2017.
  • Its 4-year average for Return on Equity is 1.0%, with a median of 0.7% in 2015.
  • Over the last 5 years, Eledon Pharmaceuticals' Return on Equity had its largest YoY gain of 9600bps in 2017, and its largest YoY loss of -21800bps in 2017.
  • Over the past 4 years, Eledon Pharmaceuticals' Return on Equity (Quarter) stood at 0.23% in 2014, then tumbled by -197bps to 0.67% in 2015, then crashed by -308bps to 2.76% in 2016, then soared by 87bps to 0.35% in 2017.
  • Its Return on Equity was 0.35% in Q3 2017, compared to 0.72% in Q2 2017 and 2.94% in Q1 2017.